VivoSeq
Other

Arthropathy

16

Pipeline Programs↗

3

Active Trials↗

14

Companies Involved↗

Arthropathy is an emerging landscape with 16 programs across 14 companies. The most active players are TWi Biotechnology, Inc., Almaject, Revance Therapeutics, Inc.. 6 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

6/100

Mech. Concentration

22/100

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TWi Biotechnology, Inc.

1 program

Phase 2A

Almaject

1 program

Phase 2R

Revance Therapeutics, Inc.

1 program

Phase 2Q

Quince Therapeutics S.p.A.

1 program

Phase 3Amgen logo

Amgen

1 program

Phase 3A

Amring

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

15 of 19 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody211%Protein / enzyme15%Peptide15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

18

clinical trials

Completed11 · 61%
Terminated2 · 11%
Unknown status2 · 11%
Recruiting2 · 11%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

18 trials

Long-term Follow-up of Patients Undergoing Aseptic Revision Hip Arthroplasty or Complex Primary Hip Arthroplasty Treated at University Hospitals Leuven
Recruiting·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT07481448·200 enrolled
Prosthesis Versus Active Exercise Program in Patients With Rotator Cuff Arthropathy Eligible For Reverse Shoulder Arthroplasty: the ReAct Multicenter, Randomized Controlled Trial
Recruiting·UUniversity of Aarhus·Preclinical·NCT04864158·102 enrolled
Comprehensive Reverse Shoulder: Porous Augmented Glenoid Baseplate and Mini Humeral Tray Post-Market Clinical Follow-up Study
Active, not recruiting·ZZimmer Biomet·Preclinical·NCT03726554·99 enrolled
A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy
Completed·TTWi Biotechnology, Inc.·Phase 2·NCT02994147·22 enrolled
Steroid Injection for Sickle Cell Arthropathy Pain Therapy
Completed·SSalem Anaesthesia Pain Clinic·N/A·NCT05983055·50 enrolled
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
Completed·WWestern University of Health Sciences·Phase 3·NCT03174366·7 enrolled
Allogeneic BM-MSCs in Patients with Lumbar Facet Arthropathy
Completed·MMayo Clinic·Phase 1·NCT04410731·10 enrolled
Low-Cost Platelet-Rich Plasma for Hemarthropathy
Completed·UUniversity of Utah·N/A·NCT06543368·14 enrolled
Does Botulinum A Toxin Help With Pain From Rotator Cuff Arthropathy?
Completed·RRoyal Devon and Exeter NHS Foundation Trust·Phase 2·NCT02512536·10 enrolled
Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
Completed·TTri-Service General Hospital·N/A·NCT02601170·22 enrolled
RANKL Antibody for Acute Charcot Neuro-osteoarthropathy
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 4·NCT05797259·78 enrolled
Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2·NCT02023411·20 enrolled
Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy
Completed·Pfizer logoPfizer·Phase 4·NCT00420303·24 enrolled
Ambispective Study to Assess the Safety and the Performance of SAGITTA EVL R Stem
Completed·SSociete dEtude, de Recherche et de Fabrication·N/A·NCT06096155·46 enrolled
Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy
Terminated·TTremeau Pharmceuticals, Inc.·Phase 3·NCT04684511·2 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)